vs
迈梭电子（MEI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
迈梭电子的季度营收约是再鼎医药的1.9倍（$246.9M vs $127.1M），再鼎医药同比增速更快（17.1% vs -15.6%），迈梭电子自由现金流更多（$-11.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -2.5%）
迈梭电子是一家总部位于美国伊利诺伊州芝加哥的跨国企业，主要业务涵盖工程研发、生产制造与销售服务，目前在全球14个国家设有超过35个运营网点，全球员工总数约6500人。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MEI vs ZLAB — 直观对比
营收规模更大
MEI
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出32.7%
-15.6%
自由现金流更多
MEI
多$15.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-2.5%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $246.9M | $127.1M |
| 净利润 | $-9.9M | — |
| 毛利率 | 19.3% | 51.0% |
| 营业利润率 | 1.2% | -54.6% |
| 净利率 | -4.0% | — |
| 营收同比 | -15.6% | 17.1% |
| 净利润同比 | -518.8% | — |
| 每股收益（稀释后） | $-0.28 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEIZLAB
| Q4 25 | $246.9M | $127.1M | ||
| Q3 25 | $240.5M | $115.4M | ||
| Q2 25 | $257.1M | $109.1M | ||
| Q1 25 | $239.9M | $105.7M | ||
| Q4 24 | $292.6M | $108.5M | ||
| Q3 24 | $258.5M | $101.8M | ||
| Q2 24 | $277.3M | $100.1M | ||
| Q1 24 | $259.5M | $87.1M |
净利润MEIZLAB
| Q4 25 | $-9.9M | — | ||
| Q3 25 | $-10.3M | $-36.0M | ||
| Q2 25 | $-28.3M | $-40.7M | ||
| Q1 25 | $-14.4M | $-48.4M | ||
| Q4 24 | $-1.6M | — | ||
| Q3 24 | $-18.3M | $-41.7M | ||
| Q2 24 | $-57.3M | $-80.3M | ||
| Q1 24 | $-11.6M | $-53.5M |
毛利率MEIZLAB
| Q4 25 | 19.3% | 51.0% | ||
| Q3 25 | 18.1% | 59.5% | ||
| Q2 25 | 7.6% | 60.6% | ||
| Q1 25 | 17.2% | 63.6% | ||
| Q4 24 | 19.8% | 61.5% | ||
| Q3 24 | 17.3% | 64.1% | ||
| Q2 24 | 12.8% | 64.9% | ||
| Q1 24 | 14.3% | 61.4% |
营业利润率MEIZLAB
| Q4 25 | 1.2% | -54.6% | ||
| Q3 25 | 0.5% | -42.3% | ||
| Q2 25 | -9.2% | -50.3% | ||
| Q1 25 | -0.9% | -53.3% | ||
| Q4 24 | 3.2% | -62.6% | ||
| Q3 24 | -2.9% | -66.6% | ||
| Q2 24 | -22.2% | -76.0% | ||
| Q1 24 | -1.2% | -80.7% |
净利率MEIZLAB
| Q4 25 | -4.0% | — | ||
| Q3 25 | -4.3% | -31.2% | ||
| Q2 25 | -11.0% | -37.3% | ||
| Q1 25 | -6.0% | -45.8% | ||
| Q4 24 | -0.5% | — | ||
| Q3 24 | -7.1% | -40.9% | ||
| Q2 24 | -20.7% | -80.2% | ||
| Q1 24 | -4.5% | -61.4% |
每股收益（稀释后）MEIZLAB
| Q4 25 | $-0.28 | $-0.05 | ||
| Q3 25 | $-0.29 | $-0.03 | ||
| Q2 25 | $-0.79 | $-0.04 | ||
| Q1 25 | $-0.41 | $-0.04 | ||
| Q4 24 | $-0.05 | $-0.09 | ||
| Q3 24 | $-0.52 | $-0.04 | ||
| Q2 24 | $-1.62 | $-0.08 | ||
| Q1 24 | $-0.33 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $118.5M | $689.6M |
| 总债务越低越好 | $332.5M | — |
| 股东权益账面价值 | $679.3M | $715.5M |
| 总资产 | $1.3B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.49× | — |
8季度趋势，按日历期对齐
现金及短期投资MEIZLAB
| Q4 25 | $118.5M | $689.6M | ||
| Q3 25 | $121.1M | $717.2M | ||
| Q2 25 | $103.6M | $732.2M | ||
| Q1 25 | $103.8M | $757.3M | ||
| Q4 24 | $97.0M | $779.7M | ||
| Q3 24 | $111.3M | $616.1M | ||
| Q2 24 | $161.5M | $630.0M | ||
| Q1 24 | $122.9M | $650.8M |
总债务MEIZLAB
| Q4 25 | $332.5M | — | ||
| Q3 25 | $323.4M | — | ||
| Q2 25 | $317.6M | — | ||
| Q1 25 | $327.9M | — | ||
| Q4 24 | $340.6M | — | ||
| Q3 24 | $296.0M | — | ||
| Q2 24 | $330.9M | — | ||
| Q1 24 | $331.3M | — |
股东权益MEIZLAB
| Q4 25 | $679.3M | $715.5M | ||
| Q3 25 | $688.1M | $759.9M | ||
| Q2 25 | $693.3M | $791.7M | ||
| Q1 25 | $704.3M | $810.8M | ||
| Q4 24 | $738.3M | $840.9M | ||
| Q3 24 | $744.4M | $667.7M | ||
| Q2 24 | $766.0M | $704.2M | ||
| Q1 24 | $835.0M | $762.2M |
总资产MEIZLAB
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.4B | $985.3M | ||
| Q2 24 | $1.4B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
负债/权益比MEIZLAB
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.43× | — | ||
| Q1 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-11.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | -4.7% | -21.0% |
| 资本支出强度资本支出/营收 | 1.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $52.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MEIZLAB
| Q4 25 | $-7.4M | $-26.0M | ||
| Q3 25 | $25.1M | $-32.0M | ||
| Q2 25 | $35.4M | $-31.0M | ||
| Q1 25 | $28.1M | $-61.7M | ||
| Q4 24 | $-48.0M | $-55.8M | ||
| Q3 24 | $10.9M | $-26.8M | ||
| Q2 24 | $24.9M | $-42.2M | ||
| Q1 24 | $28.8M | $-90.1M |
自由现金流MEIZLAB
| Q4 25 | $-11.6M | $-26.7M | ||
| Q3 25 | $18.0M | $-35.0M | ||
| Q2 25 | $26.3M | $-33.9M | ||
| Q1 25 | $19.6M | $-63.2M | ||
| Q4 24 | $-58.4M | $-58.4M | ||
| Q3 24 | $-2.7M | $-28.2M | ||
| Q2 24 | $15.8M | $-42.9M | ||
| Q1 24 | $12.2M | $-91.1M |
自由现金流率MEIZLAB
| Q4 25 | -4.7% | -21.0% | ||
| Q3 25 | 7.5% | -30.4% | ||
| Q2 25 | 10.2% | -31.1% | ||
| Q1 25 | 8.2% | -59.9% | ||
| Q4 24 | -20.0% | -53.8% | ||
| Q3 24 | -1.0% | -27.7% | ||
| Q2 24 | 5.7% | -42.9% | ||
| Q1 24 | 4.7% | -104.5% |
资本支出强度MEIZLAB
| Q4 25 | 1.7% | 0.5% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 3.5% | 2.6% | ||
| Q1 25 | 3.5% | 1.5% | ||
| Q4 24 | 3.6% | 2.4% | ||
| Q3 24 | 5.3% | 1.3% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 6.4% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEI
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
